Table 6 Relationship between serum CA125 half life and survival in ovarian cancer
From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
First Author, Year, Study Place | Data Collection | Study Design | Sample Size | Groups being Compared | RR/HR, (95% CI), P-Value | Conclusion | Variables Adjusted for |
|---|---|---|---|---|---|---|---|
Riedinger JM, 2008, France [64] | 1996 to 2000 | Multicentric Retrospective study | 130 | Non-assessable, ≤ 14 days and mono-exponential decay, ≤ 14 days and bi-exponential decay, > 14 days | NA | The CA125 group classification was found to be an independent prognostic factor only for DFS | CA125 nadir, chemotherapy courses, residual tumor |
Riedinger JM, 2006, France [38] | 1988 to 1996 | Multicentric Retrospective study | 553 | ≤ 14 days, > 14 days | 2.04 (1.58-2.63), < 0.0001 | Among well-established prognostic factors in ovarian cancers, CA125 half-life and nadir concentration bear a strong and independent prognostic value | FIGO stage, residual tumor, age, CA125 nadir |
Gadducci A, 2004, Italy [65] | 1996 to 2002 | Retrospective study | 71 | ≤ 14 days, > 14 days | 3.11 (1.22--7.98), 0.0181 | Serum CA125 half-life was an independent prognostic factor for the chance of achieving a complete response to treatment as well as for progression-free survival and overall survival | Age, Histology FIGO stage, Residual disease, chemotherapy regimen, CA125 percentage reduction after the first cycle of chemotherapy |
Colakovic S, 2000, Yugoslavia [51] | NA | Retrospective study | 222 | < 20 days, > 20 days | NA, 0.007 | CA125 half life can divide patients into good and poor prognostic groups early during chemotherapy | Therapeutic response Karnofsky index, residual disease, tumor grade, CA125 kinetics |
Munstedt K, 1997, Germany [63] | 1987 to 1994 | Retrospective study | 85 | < 20 days, > 20 days | 0.6184 | Serum CA125 half-life did not have any significant correlation with survival | Age, FIGO stage, Histology, grades |
Gadducci A, 1995, Italy [40] | 1986 to 1992 | Multicentric Retrospective study | 225 | < 25 days, ≥ 25 days | 2.13 (1.23-3.68), 0.0073 | Serum CA125 half-life during early chemotherapy was an independent prognostic factor for both achievement of a pathological complete response and survival | FIGO stage, Tumor grade, size of residual disease, CA125 level |
Rosman M, 1994, Connecticut [66] | June 1985 to July 1989 | Retrospective study | 51 | ≤ 12 days, > 12 days | 3.6 (1.8-7.4), < 0.001 | In those patients in whom residual small volume disease after primary surgery indicates a good prognosis, minimum CA125 and CA125 t1/2 during chemotherapy can further categorize patients into favourable and unfavourable prognostic groups | FIGO stage, tumor grade, residual disease, CA125 |
Yedema C A, 1993, Netherlands [52] | July 1984 to Dec 1990 | Retrospective study | 60 | ≤ 20 days, > 20 days | 9.17 (1.49-56.3), 0.01 | CA125 half-life provides an independent prognostic factor for survival in stage III-IV patients early in the course of therapy | Stage, histology, grade, tumor rest |
Hogberg T, 1990, Sweden [67] | 1984-1987 | Prospective study | 72 | ≤ 8 days, 8 - ≤ 12 days, 12 < - ≤ 16 days, > 16 days | NA, 0.003 | The patients with a short serum CA125 half-life had a significantly better probability of survival | Age, histology FIGO stage, residual tumor, grade |
Hunter VJ, 1990, Durham [68] | March 1984 to Jan 1989 | Prospective study | 54 | ≤ 20 days, > 20 days | NA, < 0.015 | Overall survival was significantly greater in patients with a CA125 half life ≤ 20 days | NA |
Hawkins RE, 1989, London [69] | NA | Prospective study | 29 | < 20 days, 20-40 days, > 40 days | 3.7 (0.7-20.1), 0.001; 27.8 (4.0-193), 0.001 | CA125 half life was independent prognostic indicator for survival | Residual tumor, stage, ascites |
van der Burg ME, 1988, Netherlands [44] | Sept 1979 to Dec 1983 | Consecutive case series | 85 | < 20 days, ≥ 20 days | NA | The half-life of CA125 appeared to be significantly and independently correlated with progression rate and progression-free survival | FIGO stage, histology, histological grade, postoperative tumor size |